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Abstract
Background: Women with a history of mainly severe and early onset preeclampsia have an increased risk of future
cardiovascular disease. During these complicated pregnancies increased levels of anti-angiogenic factors can be found. We
hypothesize that women with a history of severe very early onset preeclampsia still have increased levels of these
biomarkers years after this pregnancy, resulting in increased risk for cardiovascular disease.
Methods: Twenty women with severe early onset preeclampsia before 24 weeks’ gestation, who delivered between 1993–
2003 in a tertiary referral centre and twenty matched controls with uncomplicated pregnancies and healthy term infants,
were addressed for participation in the study. Venous plasma samples were analyzed for basic fibroblast growth factor
(bFGF), placental growth factor (PLGF), soluble fms-like tyrosine kinase-1 (sFlt-1), vascular endothelial growth factor (VEGF),
E- and P-selectin, soluble intercellular adhesion molecule-3 (sICAM-3) and thrombomodulin by ELISA.
Results: Sixteen case subjects and 18 control subjects consented participation. The median time interval index pregnancy to
study was 9.4 and 9.7 years for cases and controls, respectively. Median levels for cases-controls (p-value) were not different;
bFGF: 17.43–11.11 pg/mL (0.33), sFlt-1: 102.98–101.92 pg/ml (0.84), PLGF: 3.57–4.20 pg/mL (0.38), VEGF: 64.05–45.72 pg/mL
(0.73), E-selectin: 5.11–4.68 ng/mL (0.20), P-selectin: 85.35–71.69 ng/mL (0.69), sICAM-3: 0.42–0.63 ng/mL (0.41) and
Thrombomodulin: 0.92–0.93 ng/mL (0.59).
Conclusion: There were no differences in angiogenic biomarkers between women with a history of severe early onset
preeclampsia versus uncomplicated pregnancy almost 10 years later, suggesting that these angiogenic factors will not
contribute to the early detection of women at risk for future cardiovascular disease.
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Introduction
Preeclampsia occurs in 3–5% of pregnancies and is a major
cause of both fetal and maternal morbidity and mortality
worldwide [1,2]. The clinical features of the maternal syndrome,
hypertension and proteinuria, are based on widespread maternal
endothelial dysfunction and microangiopathy [3]. Although, the
cause of preeclampsia is unknown, shallow invasion of the
trophoblast into the spiral arteries of the placental bed appear to
play a key role [4]. Increasing numbers of studies focus on altered
expression of angiogenic and anti-angiogenic factors as a result of
this impaired cytotrophoblast invasion leading to hypoxia. Current
evidence suggests that excess of anti-angiogenic factors mediates
symptoms and signs of preeclampsia [5–7].
Preeclampsia reflects not only impact on pregnancy itself;
epidemiological studies have demonstrated an association between
preeclampsia and maternal cardiovascular disease in later life [8–
11]. Cardiovascular disease (CVD) and preeclampsia, which
occurs most often in term pregnancies share many risk factors
and pathophysiological abnormalities like hypertension, insulin
resistance and increased systemic inflammatory response. Classic
risk factors for CVD are hypertension, hyperlipidemia, insulin
resistance, and obesity. In the last decade several studies have been
published regarding other biomarkers as risk factor for CVD [12–
18]. These novel factors comprise of angiogenic factors such as
vascular endothelial growth factor (VEGF), placental growth
factor (PLGF) and basic fibroblast growth factor (bFGF), anti-
angiogenic factors such as soluble fms-like tyrosine kinase-1 (sFlt-1)
and soluble endoglin (s-Eng) and adhesion molecules such as
intercellular adhesion molecule (ICAM), vascular cell adhesion
molecule (VCAM), soluble P-selectin and soluble E-selectin. We
hypothesize that because of the shared mechanism of hypertensive
disorders in pregnancy and CVD later in life, distinct levels of
angiogenic and anti angiogenic factors are expressed in women
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who had preeclampsia and women who had an uncomplicated
pregnancy [5,19]. In addition, women with a history of severe
early onset preeclampsia are at the highest risk of CVD and might
express distinguished angiogenic risk factors which could be used
as markers for secondary preventive measures [20]. Therefore, we
studied angiogenic risk factors in a cohort of women with a history
of severe preeclampsia with an onset before 24 weeks’ gestation
(cases) and healthy women with uncomplicated pregnancies
(controls). The results of classic cardiovascular risk factors in this
rare cohort were published in 2008 [21]. This study showed that
on average 5 years (range 4–10 years) after the pregnancy
complicated by severe early onset preeclampsia 55% of cases
versus 10% of controls had chronic hypertension. There was no
difference in BMI, lipid profiles and glucose intolerance between
both groups. These findings suggest a more hypertension related
vascular etiology rather than a metabolic syndrome origin in
severe early onset preeclampsia.
Methods
Participants
Twenty women who had been admitted to the University
Medical Center Rotterdam between 1993 and 2003, with the
diagnosis severe early onset preeclampsia before 24 weeks’
gestation and 20 healthy matched control patients after uncom-
plicated term pregnancies, were addressed for participation in the
current study on novel cardiovascular risk factors. Sixteen of 20
cases and 18 of 20 controls consented to participate. Two cases
and two controls did not respond to our mailing and two cases
refrained from participation as they stated difficulties in blood
sampling. All non-participants were of Afro-Caribbean origin.
These women did not differ in maternal complications or fetal
outcome at time of the index pregnancy from the participating
women. The study was approved by the Medical Ethics
Committee of the University Medical Center Rotterdam (MEC
2005-185).
Severe preeclampsia was defined as an absolute diastolic blood
pressure of $110 mm Hg and proteinuria ($2+ [1 g/l]) on a
catheterized specimen on admission, or the occurrence of
preeclampsia (blood pressure $140 mmHg systolic or
$90 mmHg diastolic measured on at least two occasions in
women normotensive before 20 weeks gestation and proteinuria
$300 mg/24 h (or $2+ on dipstick of voided specimen) in
combination with eclampsia or HELLP syndrome. HELLP
(hemolysis, elevated liver enzymes, and low platelets) was defined
as thrombocytes ,1006109/l, and both ASAT (aspartate
aminotransferase) and ALAT (alanine aminotransferase) .70 U/
l and lactate dehydrogenase .600 U/L.
Data collection
Venous blood samples were obtained in EDTA collection tubes.
A standard laboratory procedure was implemented for the
centrifugation, aliquoting and storage of samples at 270uC until
assay. Plasma was assayed for bFGF, PLGF, sFlt-1, VEGF, E- and
P-selectin, sICAM-3 and thrombomodulin by ELISA (MSDH 96-
Well MULTI-SPOTH Vascular Injury Panel I Assay and MSDH
MULTI-SPOTH Human Growth Factor I Assay). Samples below
detection level were excluded from analyses (bFGF: 2 cases and 1
control, PLGF in 7 cases and 10 controls). All assays were
performed by a single investigator (C.B.) and were analyzed
blindly and in duplicate. The inter and intra assay coefficients of
variation were less than 10%.
Statistical analyses
Continuous variables are expressed as medians with ranges.
General characteristics were compared between groups using
independent T-test and x2 statistics test where appropriate.
The statistical package used was SPSS 18.0 (Chicago, Illinois). A
p-value of ,0.05 was considered significant.
Results
General characteristics of participants are demonstrated in
Table 1. As expected no differences between women who had
preeclampsia and uncomplicated pregnancies were found for
maternal age, parity, race and time since index pregnancy (9.4
years vs. 9.7 years in cases and controls, respectively). With regard
to the index pregnancy cases delivered significantly earlier and
delivered neonates with significantly lower birth weights. In the
current study, almost ten years after the index pregnancy, six
women (38%) used antihypertensive medication of which five
patients had chronic hypertension at time of their (index)
pregnancy complicated with severe, early onset preeclampsia
before 24 weeks’ gestation. None of the controls used anti
hypertensive medication.
The results of angiogenic risk factors are depicted in table 2.
None of the angiogenic factors were significantly different between
cases and controls.
Discussion
We found no differences in angiogenic risk factors between
women with a history of severe preeclampsia with an onset before
24 weeks’ gestation (cases) and healthy women who had an
uncomplicated pregnancy (controls) ten years after their pregnan-
cy. Although, hypertension was found more prevalent amongst
cases, antihypertensive drug use was not associated with higher
Table 1. General characteristics of women with severe, very
early onset preeclampsia and controls.
Cases Controls p value
n=16 n=18
Index pregnancy data
Age, years 32.5 (29.1–36.2) 31.7 (28.2–35.2) 0.77
Parity 0.37
Nulliparous, n (%) 10 (63) 11 (61)
Race, n (%) 0.50
Caucasian 12 (75) 12 (67)
African (-Caribbean) 2 (12.5) 4 (22)
Asian 2 (12.5) 2 (11)
Gestational age at delivery,
weeks
22.8 (22.3–23.3) 40.2 (38.6–41.1) ,0.001
Birth weight, grams 520 (415–600) 3373 (2873–3648) ,0.001
Data at present study
Age, years 42.9 (38.8–45.1) 41.6 (38.8–45.7) 0.86
Time since index pregnancy,
years
9.4 (9.2–10.3) 9.7 (9.3–10.9) 0.81
Antihypertensive medication,
n (%)
6 (38) 0 0.01
Data are expressed as median (interquartile range).
doi:10.1371/journal.pone.0043637.t001
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levels of angiogenic biomarkers. Our conclusion has to be taken
with some caution as the sample size of the cohort is small.
However, the cohort comprises of women with extreme early and
severe disease and a substantial number of women have chronic
hypertension, so one would expect this particular group of women
to present higher levels of these angiogenic biomarkers. Data on
dietary salt intake, which influences levels of angiogenic factors,
were not available in our study. Regarding the effect of phases of
menstrual cycle at time of blood sampling there was no difference
between both groups. Among the cases 8 women had spontaneous
cycles and 8 women used oral contraceptives. In four women
(50%) with spontaneous cycles blood samples were taken in the
follicular phase. Among 18 controls 12 women had spontaneous
cycles, 4 women used oral contraceptives and 2 women were post
menopausal. Preovulatory blood sampling occurred in 5 women
(42%).
Angiogenic and anti-angiogenic factors have been studied
during normal and preeclamptic pregnancies. Increased levels of
anti-angiogenic factors (sFlt-1 and s-Eng) and lower levels of
angiogenic factors (VEGF and PLGF) have been described in
women with severe and/or early onset preeclampsia [5,22–26].
Literature on these factors focuses mainly on discriminatory and
predictive abilities for preeclampsia as altered levels of angiogenic
factors are detectable as early as in the first trimester [19,27–29].
In contrast, knowledge of angiogenic factors after preeclamptic
pregnancies is scarce. Noori et al. [30] studied angiogenic factors
and maternal vascular function prospectively in 159 women
during pregnancy until 12 weeks post partum. Levels of, PLGF,
sFlt-1 and s-Eng showed a 50-fold, 25-fold and 2.5-fold fall
respectively, from their highest level in the third trimester to the
lowest level 12 weeks post partum in women with uncomplicated
pregnancies. However, post partum PLGF levels in patients with
preeclampsia and gestational hypertension were significantly
higher compared to women who had been normotensive during
pregnancy. The fall of 3rd trimester to postpartum PLGF levels in
normotensive women is higher compared to women with
hypertensive pregnancies. They suggest that persistence of
increased levels of PLGF is responsible for the increased risk of
cardiovascular disease in later life. We were unable to trace any
literature with longer follow up of PLGF after pregnancies
complicated by preeclampsia. Placental growth factor is expressed
not only in placental cells but also in many non-placental cells
including endothelial cells. PLGF promotes angiogenesis and is of
major importance in pregnancy, but also stimulates atherosclerotic
intimal thickening [31]. Elevated PLGF levels were associated with
an increased risk of coronary heart disease in the Nurses’ Health
Study [12] more then ten years after a baseline test in
asymptomatic women. Data regarding their pregnancies were
not reported. In our study PLGF was below the detection limit of
the assay in almost half of the samples. It may be speculated that
the younger age and premenopausal state of most of our
participants explain the low levels.
Sattar et al. studied angiogenic risk factors in women with a
history of preeclampsia, 15–25 years after the index pregnancy
[20]. Forty women with preeclampsia and matched controls were
analyzed for ICAM-1, VCAM-1 and E-selectin. In this study the
median gestational age at delivery was near term, in contrast to
our study, in which all patients had severe preeclampsia and
delivery at 23 weeks. They found an increased concentration of
ICAM-1, which is an adhesion molecule involved in monocyte
attachment and transformation to macrophages in the vascular
wall and appears an independent predictor of coronary heart
disease [13]. To our knowledge, there are no other studies on long
term follow up after preeclampsia with respect to bFGF, VEGF,
soluble P- and E-selectin and thrombomodulin. However, at
shorter follow up after preeclampsia Wolf at al [32] found
increased levels of sFlt-1 in 29 women at 18 months postpartum
and Saxena et al [33] found increased sFlt-1 levels after
angiotensin II infusion in 10 women on average 13 months
postpartum. In both studies time of onset of preeclampsia is not
stated. Similar to our results Yinon et al [34] could not
demonstrate differences in angiogenic factors (VEGF, sFlt-1,
PLGF and s-End) in 24 women with both early onset (n = 15) and
late onset preeclampsia (n = 9) at 6–24 months postpartum. VEGF
and sFlt-1 is described to be associated with cardiovascular disease
[14,15] and sFlt-1 correlates with severity of disease [16].
Although, these findings are not consistent, VEGF seems not to
be an independent risk factor for cardiovascular disease when
adjusted for gender, age, smoking and diabetes [17]. With respect
to adhesion molecules E- and P-selectin an association with
coronary heart disease seems likely [18], however measurements in
a prospective study and meta analyses add no further predictive
information to that provided by more established risk factors [35].
It has previously been hypothesized that persistent endothelial
dysfunction caused by damaged endothelium during preeclampsia,
possibly secondary to exposure to anti-angiogenic factors, may be
responsible for these adverse long term cardiovascular outcomes.
However, the results of our study on angiogenic risk factors, which
are most likely associated with severe and early preeclampsia, do
not suggest such a pathophysiological mechanism at long term
follow up in this particular subset of patients. We speculate that the
imbalance of angiogenic factors as found in preeclamptic
pregnancies arise at the moment when the cardiovascular system
is stressed by that pregnancy. Similar to the phenomenon of
recovery of hypertension and proteinuria after preeclampsia,
which may take up to two years in some women [36], the
angiogenic imbalance seems to recover as well. In later life the
highest associations of angiogenic factors with cardiovascular
disease seem to be found in patients with manifest cardiovascular
disease, and may be a reflection of metabolic alterations,
endothelial activation and low grade inflammation known to be
present in that situation.
In summary, we found no differences in angiogenic biomarkers
between women with a history of severe preeclampsia and control
women ten years after pregnancy. These findings suggest that
these angiogenic biomarkers are not useful for risk assessment for
future cardiovascular disease in these women.
Table 2. Angiogenic risk factors in women with severe, very
early onset preeclampsia and controls.
Cases Controls p-value
N=16 N=18
bFGF, pg/mL 17.43 (6.11–35.23) 11.11 (4.16–31.47) 0.33
sFLT-1, pg/mL 102.98 (89.43–109.64) 101.92 (77.63–123.62) 0.84
VEGF, pg/mL 64.05 (50.45–101.87) 45.72 (32.39–78.76) 0.73
E-selectin, ng/mL 5.11 (2.89–7.74) 4.68 (3.27–7.82) 0.20
P-selectin, ng/mL 85.35 (41.94–102.20) 71.69 (58.13–108.00) 0.69
s-ICAM-3, ng/mL 0.42 (0.42–0.73) 0.63 (0.43–0.73) 0.41
Thrombomodulin,
ng/mL
0.92 (0.72–1.23) 0.93 (0.75–1.09) 0.59
bFGF, pg/mL 17.43 (6.11–35.23) 11.11 (4.16–31.47) 0.33
Data are expressed in median (interquartile range).
doi:10.1371/journal.pone.0043637.t002
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